09UC37ZSupplement Left Mastoid Sinus with Autologous Tissue Substitute, Percutaneous Approach
- Billable / Specific Code
09UC37Z is a billable ICD-10-PCS procedure code for Supplement Left Mastoid Sinus with Autologous Tissue Substitute, Percutaneous Approach. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRGs 135, 136. The root operation Supplement involves putting in or on biological or synthetic material that physically reinforces and/or augments the function of a portion of a body part.
Code Identity
PCS Table Breakdown
Each ICD-10-PCS code is built from seven characters, each an axis of the procedure. Hover or tap the icons for the official CMS definitions.
| Position | Designation | Value | Meaning |
|---|---|---|---|
| 1 | Section | 0 | Medical and Surgical |
| 2 | Body System | 9 | Ear, Nose, Sinus |
| 3 | Operation | U | Supplement |
| 4 | BodyPart | C | Mastoid Sinus, Left |
| 5 | Approach | 3 | Percutaneous |
| 6 | Device | 7 | Autologous Tissue Substitute |
| 7 | Qualifier | Z | No Qualifier |
Code History
- 09QC3ZZ — Repair Left Mastoid Sinus, Percutaneous Approach
Similar Procedure Codes
Questions About 09UC37Z
Is 09UC37Z a billable code?
Yes. 09UC37Z is a complete seven-character ICD-10-PCS code, specific enough to report Supplement Left Mastoid Sinus with Autologous Tissue Substitute, Percutaneous Approach on inpatient claims from October 1, 2025 through September 30, 2026.
What do the characters in 09UC37Z mean?
09UC37Z breaks down character by character: the 1st character 0 is the Section (Medical and Surgical); the 2nd character 9 is the Body System (Ear, Nose, Sinus); the 3rd character U is the Operation (Supplement); the 4th character C is the BodyPart (Mastoid Sinus, Left); the 5th character 3 is the Approach (Percutaneous); the 6th character 7 is the Device (Autologous Tissue Substitute); the 7th character Z is the Qualifier (No Qualifier).
What MS-DRG does 09UC37Z group to?
On an inpatient stay, Supplement Left Mastoid Sinus with Autologous Tissue Substitute, Percutaneous Approach maps to MS-DRGs 135, 136, with relative weights from 1.0153 to 2.1152. The MS-DRG sets the fixed Medicare payment for the stay.
